130 related articles for article (PubMed ID: 38009290)
1. Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment.
Hong H; Cho M; Lim C; Choi WM; Lee D; Shim JH; Kim KM; Lim YS; Lee HC; Choi J
Aliment Pharmacol Ther; 2024 Feb; 59(4):515-525. PubMed ID: 38009290
[TBL] [Abstract][Full Text] [Related]
2. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B.
Ogawa E; Nomura H; Nakamuta M; Furusyo N; Koyanagi T; Dohmen K; Ooho A; Satoh T; Kawano A; Kajiwara E; Takahashi K; Azuma K; Kato M; Shimoda S; Hayashi J;
Liver Int; 2020 Jul; 40(7):1578-1589. PubMed ID: 32304611
[TBL] [Abstract][Full Text] [Related]
3. Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Szeto CC; Wong VW
Aliment Pharmacol Ther; 2018 Nov; 48(9):984-992. PubMed ID: 30125952
[TBL] [Abstract][Full Text] [Related]
4. Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Jung CY; Kim HW; Lee JI; Lee HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 Nov; 42(11):2408-2417. PubMed ID: 35943853
[TBL] [Abstract][Full Text] [Related]
5. Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Aliment Pharmacol Ther; 2022 Aug; 56(4):713-722. PubMed ID: 35735794
[TBL] [Abstract][Full Text] [Related]
6. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
7. Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy.
Lee JS; Jung CY; Lee JI; Ahn SH; Kim BS; Kim SU
Aliment Pharmacol Ther; 2023 Jul; 58(1):99-109. PubMed ID: 37114501
[TBL] [Abstract][Full Text] [Related]
8. Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B.
Jung CY; Kim HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 May; 42(5):1017-1026. PubMed ID: 35220649
[TBL] [Abstract][Full Text] [Related]
9. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease.
Tsai HJ; Chuang YW; Yang SS; Chang YZ; Chang HR; Lee TY
J Viral Hepat; 2021 Nov; 28(11):1579-1586. PubMed ID: 34464999
[TBL] [Abstract][Full Text] [Related]
10. Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study.
Ogawa E; Nakamuta M; Koyanagi T; Ooho A; Furusyo N; Kajiwara E; Dohmen K; Kawano A; Satoh T; Takahashi K; Azuma K; Yamashita N; Yamashita N; Sugimoto R; Amagase H; Kuniyoshi M; Ichiki Y; Morita C; Kato M; Shimoda S; Nomura H; Hayashi J;
Hepatol Int; 2022 Apr; 16(2):282-293. PubMed ID: 35075593
[TBL] [Abstract][Full Text] [Related]
11. Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study.
Ogawa E; Jun DW; Toyoda H; Hsu YC; Yoon EL; Ahn SB; Yeh ML; Do S; Trinh HN; Takahashi H; Enomoto M; Kawada N; Yasuda S; Tseng CH; Kawashima K; Lee HA; Inoue K; Haga H; Do AT; Maeda M; Hoang JH; Cheung R; Ueno Y; Eguchi Y; Furusyo N; Yu ML; Tanaka Y; Nguyen MH
Aliment Pharmacol Ther; 2024 Jan; 59(2):239-248. PubMed ID: 37882252
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis.
Ha I; Chung JW; Jang ES; Jeong SH; Kim JW
J Gastroenterol Hepatol; 2020 Oct; 35(10):1774-1781. PubMed ID: 32154938
[TBL] [Abstract][Full Text] [Related]
13. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
14. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients.
Tsai HJ; Chuang YW; Lee SW; Wu CY; Yeh HZ; Lee TY
Aliment Pharmacol Ther; 2018 Jun; 47(12):1673-1681. PubMed ID: 29696665
[TBL] [Abstract][Full Text] [Related]
15. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Jeong S; Shin HP; Kim HI
Intervirology; 2022; 65(2):94-103. PubMed ID: 34731856
[TBL] [Abstract][Full Text] [Related]
16. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
17. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide.
Buti M; Marcos-Fosch C; Esteban R
Liver Int; 2021 Jun; 41 Suppl 1():9-14. PubMed ID: 34155802
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study.
Mak LY; Hoang J; Jun DW; Chen CH; Peng CY; Yeh ML; Kim SE; Huang DQ; Jeong JY; Yoon E; Oh H; Tsai PC; Huang CF; Ahn SB; Trinh H; Xie Q; Wong GLH; Enomoto M; Shim JJ; Lee DH; Liu L; Kozuka R; Cho YK; Jeong SW; Kim HS; Trinh L; Dao A; Huang R; Hui RW; Tsui V; Quek S; Khine HHTW; Ogawa E; Dai CY; Huang JF; Cheung R; Wu C; Chuang WL; Lim SG; Yu ML; Yuen MF; Nguyen MH
Hepatol Int; 2022 Feb; 16(1):48-58. PubMed ID: 34822056
[TBL] [Abstract][Full Text] [Related]
19. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
20. A switch from tenofovir to entecavir prior to hepatitis B treatment cessation is associated with a reduced risk of off-therapy relapse: An observational study.
Peng CW; Jeng WJ; Yang HI; Liu YC; Chien RN; Liaw YF
J Gastroenterol Hepatol; 2022 Nov; 37(11):2164-2172. PubMed ID: 35869752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
